Pharma Industry

UCLA research highlights the widespread use of non-evidence-based treatments during the COVID-19 pandemic, raising concerns about the role of misinformation and health care spending.

Both sides support revising laws for PBM market, but Democrats and Republicans disagree on potential Medicaid changes.

Prevention beats treatment for everyone — patients, payers and investors.

A study of the medical economics of ultraprocessed foods, diabetes and pharmaceutical revenues.

What new treatments mean for practices and patients.

An expert on antimicrobial resistance discusses how it involves patients in local doctors’ offices and around the world.

Study examined Amazon’s RxPass to see how it affected medication adherence and cost

An infectious disease expert describes the state of AMR – and how to fight it.

An infectious disease expert describes the state of AMR – and how to fight it.

An infectious disease expert describes the state of AMR – and how to fight it.

An infectious disease expert describes the state of AMR – and how to fight it.

An infectious disease expert describes the state of AMR – and how to fight it.

An infectious disease expert describes the state of AMR – and how to fight it.

Proponents say the surgical procedures are underutilized and misunderstood in contemporary medicine.

With high demand but high prices for antiobesity drugs, patients may fall for phony pharmaceuticals.

AP-NORC survey measures approval ratings.

GLP-1 drugs have proven effective in weight loss, but factors like insurance, what industry you work in, or gender, can all affect access

News outlets report opposition to Robert F. Kennedy Jr. over vaccines, reproductive issues and more.

How telehealth organizations, med spas and other nontraditional providers can lead the charge on GLP-1 medications.

Platform allows for highly precise detection of disease-specific cell-free DNA

ARS Pharmaceuticals is offering two cartons of neffy nasal spray to schools, including ongoing replacement doses

The potential CMS model would set a $2 copayment for common generic drugs in an effort to improve medication adherence.

New prices would take effect in 2027.

Rep. Greg Murphy, MD (R-North Carolina), discusses reforms he hopes Congress will consider this year.

A Weill Cornell Medicine study found that one-third of all Medicare Part D pharmacy spending and nearly 40% of specialty drug spending within Medicare Part D was through pharmacies owned by the four largest PBMs: CVS, UnitedHealth Group, Cigna and Humana.

Sheila P. Burke, chair, Government Relations and Public Policy Group, Baker Donelson Law Firm, explains how the Trump administration might approach drug pricing policy.

New statement aims to ensure access to tirzepatide as other GLP-1 drug shortages persist.

CMS Office of the Actuary publishes annual price tag; physicians got $978 billion of it.

Health care organizations respond to ‘mixed bag’ bill.

ACP also calls for action on prior authorizations.